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Abstract
Background: Predisposition to venous thrombosis may be assessed through testing for defects
and/or deficiencies of a number of hereditary factors. There is potential for confusion about which
of these tests are appropriate in which settings. At least one set of recommendations has been
published to guide such testing, but it is unclear how widely these have been disseminated.
Methods: We performed a retrospective analysis of laboratory orders and results at a national
referral laboratory to gain insight into physicians' ordering practices, specifically comparing them
against the ordering practices recommended by a 2002 College of American Pathologists (CAP)
consensus conference on thrombophilia testing. Measurements included absolute and relative
ordering volumes and positivity rates from approximately 200,000 thrombophilia tests performed
from September 2005 through August 2006 at a national reference laboratory. Quality control data
were used to estimate the proportion of samples that may have been affected by anticoagulant
therapy. A sample of ordering laboratories was surveyed in order to assess potential measurement
bias.
Results: Total antigen assays for protein C, protein S and antithrombin were ordered almost as
frequently as functional assays for these analytes. The DNA test for factor V Leiden was ordered
much more often than the corresponding functional assay. In addition, relative positivity rates
coupled with elevations in prothrombin time (PT) in many of these patients suggest that these tests
are often ordered in the setting of oral anticoagulant therapy.
Conclusion: In this real-world setting, testing for inherited thrombophilia is frequently at odds
with the recommendations of the CAP consensus conference. There is a need for wider
dissemination of concise thrombophilia testing guidelines.
Background
Venous thrombosis is a common clinical problem. A
national hospital discharge database estimates that in
2003, there were 177,000 discharges from U.S. hospitals
with an ICD9-CM diagnosis code for pulmonary embo-
lism (415.1) and 424,000 with a diagnosis code for
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venous thrombosis (453.0 through 453.9)[1]. A number
of heritable disorders predisposing to thrombosis have
been identified, including deficiencies and/or defects of
protein C, protein S, antithrombin, factor V and factor II
(prothrombin); patients presenting with deep vein
thrombosis or pulmonary embolism are often tested for
these defects. Given the range of tests, and particularly the
existence of multiple tests for most of these analytes (e.g.
protein S total antigen, free antigen and activity), there is
potential for confusion about which tests to order and
when to order them. Indeed, Somma et al. found that a
significant proportion of orders appeared not to be clini-
cally indicated in their study of 200 consecutive throm-
bophilia panel orders at an academic medical center[2].
The College of American Pathologists convened a consen-
sus conference in 2002 to address diagnostic testing for
thrombophilia, with findings published in series of arti-
cles in a pathology journal[3] as well as on the CAP web-
site[4]. The findings are not currently published in the
National Guidelines Clearinghouse[5]. For purposes of
this study, the CAP recommendations were considered to
represent diagnostic best practices as described by coagu-
lation experts.
Among the large number of recommendations issued
were several which address the choice of methodology for
initial testing (Table 1). If physicians are ordering in a
manner consistent with these recommendations, this
should be reflected in the order volumes seen in the clin-
ical laboratory. For example, the conference recom-
mended that testing for antithrombin deficiency should
begin with a functional assay[6]. If the patient is found to
be deficient, then a total antigen assay may be useful in
subclassifying the patient's defect. If this recommendation
were followed, then the laboratory would expect the
number of antithrombin total antigen assays ordered to
be less than or equal to the number of positive (i.e. results
less than the lower limit of the reference interval) anti-
thrombin functional assays. Furthermore, the laboratory
would not expect the functional and total antigen assays
to be ordered on the same specimen in most cases.
Conference recommendations also addressed the timing
of testing. Since anticoagulation and acute thrombosis
can lower levels of protein C, protein S and antithrombin,
it is preferable that testing for these be performed when
the patient has recovered from the acute event and is not
on anticoagulant therapy [6-8]. Anecdotal experience has
suggested this recommendation is often not followed.
The purpose of our study was to estimate the extent to
which thrombophilia test ordering patterns as observed at
a national reference laboratory are consistent with diag-
nostic best practices as represented by the CAP consensus
conference recommendations.
Methods
We obtained the results of all protein C, protein S, anti-
thrombin, factor V Leiden (FVL)/activated protein C
(APC) resistance, and prothrombin G20210A assays per-
formed at Associated Regional and University Patholo-
gists (ARUP Laboratories) between September 1, 2005
and August 31, 2006. There were a total of 197,771 orders
for these tests during this period. ARUP is a reference lab-
oratory owned by the University of Utah that serves sev-
eral hundred hospital and regional laboratory clients
nationwide. ARUP maintains a long term data repository
containing laboratory orders and results along with lim-
ited demographic data such as age and sex of the patient,
but no clinical data.
To address the issue of overall test selection, we examined
the relative ordering volumes for the different tests availa-
ble for each disorder. For protein C and antithrombin, we
calculated the ratio of activity tests to total antigen tests.
The former were considered by the consensus conference
to be appropriate as part of the initial workup of patients,
whereas the latter were considered to be only appropriate
in the followup of patients with a demonstrated defi-
ciency[6,7]. For protein S, we calculated the ratio of activ-
ity tests plus free antigen tests to total antigen tests, since
the conference considered protein S free antigen to be an
alternative first-line test[8]. For activated protein C resist-
ance, we calculated the ratio of APC resistance functional
assays to FVL DNA-based assays; both the CAP conference
recommendations[9] and an American College of Medical
Table 1: Selected recommendations of CAP consensus conference XXXVI: Diagnostic Issues in Thrombophilia
Initial testing for factor V Leiden may in most cases be appropriately performed by either direct DNA or functional (i.e. 2nd generation activated 
protein C resistance (APC resistance) assays [[9,10]]
Initial testing for antithrombin deficiency should be via the functional assay, rather than the total antigen assay [6]
Initial testing for protein C deficiency should be via the functional assay, rather than the total antigen assay [7]
Initial testing for protein S deficiency should be via either the functional assay or the free antigen assay, rather than the total antigen assay [8]
It is preferable that testing for antithrombin, protein C or protein S deficiency take place after the patient has recovered from the acute thrombosis. 
[[6-8]]
It is preferable that testing for antithrombin, protein C or protein S deficiency take place when the patient is not on oral anticoagulant therapy [[6-
8]].BMC Clinical Pathology 2008, 8:3 http://www.biomedcentral.com/1472-6890/8/3
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Genetics guideline[10] consider both assays to be first-
line tests.
To address the issue of timing, we considered three differ-
ent pieces of evidence: deficiency rates for different
defects, concomitant deficiency of multiple vitamin K-
dependent factors, and prothrombin time (PT) elevations.
Under the assumption that the patient population for
each of these tests is similar, then the relative positivity
rates should reflect the proportions of patients with
thrombosis who have been found in other studies to have
each of the studied defects. Most population prevalence
studies have found V Leiden mutation to be roughly an
order of magnitude more prevalent than protein S, pro-
tein C or antithrombin deficiencies[11] though it could be
argued that studies based on healthy populations could
over-represent the ratio of V Leiden mutation to these
other defects in symptomatic patients because of the pos-
sibility of acquired deficiencies. At least one study, how-
ever, has confirmed significantly higher rates of V Leiden
defects than protein C, protein S or antithrombin defi-
ciency in patients with venous thrombosis[12]. If the ratio
of V Leiden positivity in our data set were not substan-
tially higher than protein C and protein S positivity, this
could be suggestive of suboptimally timed specimens, e.g.
specimens drawn during acute thrombotic episodes and/
or during anticoagulant therapy. Since hereditary defects
for these analytes are individually uncommon even in
patients with thrombosis, results suggesting abnormali-
ties of multiple analytes on the same specimen would
likewise be evidence for suboptimal timing.
To further estimate what fraction of patients may have
been on anticoagulant therapy, we analyzed prothrombin
time (PT) and partial thromboplastin time results on
plasma specimens for which were positive for protein C
and/or protein S deficiency. (Note that for quality control
purposes, ARUP performs a PT and PTT on every plasma
specimen submitted for coagulation studies.) We set our
threshold for defining PT elevation at a level equivalent to
an international normalized ratio (INR) of 1.3. This cutoff
was chosen to include the vast majority of patients on oral
anticoagulant therapy while excluding most others. The
cutoff likely missed some patients on early anticoagulant
therapy, inadequate doses, and recently discontinued
therapy who could still have had altered protein C and/or
protein S results despite an INR less than 1.3.
Because ARUP is a primarily a referral laboratory, there
were several potential sources of bias that could have
affected the order volume ratios. One is that ARUP cannot
definitively identify which tests were ordered as part of
routine clinical care and which ones were ordered for
other reasons, such as research studies or internal labora-
tory quality control. Evidence for such non-routine-care
orders can be seen in the form of occasional transient
increases in monthly order volumes from particular client
laboratories. To qualitatively assess for the presence of
such a bias we created a filtered data set as described
below and compared test volume ratios derived from the
raw data with the same ratios derived from the filtered
data. Similar results in the two data sets would be evi-
dence against a significant bias.
Under the assumption that a client's patient mix remained
similar over the 12 month period, ARUP would expect to
receive relatively constant proportions of orders for vari-
ous tests from the client from month to month. The distri-
bution of 10 different thrombophilia tests ordered by a
client in a month was represented by a multinomial dis-
tribution ~(p1, p2, ... p10), with the numbers p1, ..., p10
representing the proportion of total volume for a particu-
lar client in a given month that was due to each of the 10
tests examined. For each client we compared these pro-
portions from each month with those from every other
month using the Multinomial Likelihood Ratio test under
the null hypothesis that the proportions from any two
months were equal. We then used the Holm test to adjust
p-values for each client-month, discarding all client-
months with a p value < 0.05 for any further infer-
ence;[13] 1.5% of all client-months were discarded at this
step.
Another potential source of bias was that some of ARUP's
client laboratories perform some of these tests in-house
while referring the other tests to ARUP. Although ARUP
does not routinely maintain data on its clients' test
menus, CAP proficiency testing participation data[14]
suggest that more laboratories perform functional assays
for protein S, protein C and antithrombin than perform
total antigen assays for the same proteins. (Note that the
CAP Surveys program is one of several external proficiency
testing programs that laboratories may enroll in to satisfy
regulatory requirements.) To evaluate this bias, we sur-
veyed a subset of clients to determine whether they were
performing any of these tests in-house. The twenty clients
with the highest volumes of orders for these tests as well
as a random sample of all other clients comprising the top
eighty percent of ARUP's order volume for these tests were
queried either by fax, phone, or e-mail. Out of 46 clients
contacted, 33 clients completed the survey. These 33 lab-
oratories represented 19.3% of the total volume of
approximately 200,000 tests analyzed in this study. The
results of the survey are displayed in Table 2. For each ana-
lyte, the test order volume ratio was separately calculated
for this set of 33 laboratories before and after excluding
laboratories offering any in-house testing for that analyte.BMC Clinical Pathology 2008, 8:3 http://www.biomedcentral.com/1472-6890/8/3
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This study was performed on fully de-identified data using
a protocol deemed by the University of Utah Institutional
Review Board to be exempt from federal regulation.
Results
Ratios of test order volumes are shown in Table 3. For pro-
tein C, protein S and antithrombin, second-line tests were
ordered almost as often as first-line tests. The ratio for
antithrombin was the most favorable of these, but total
antigen assays still made up approximately one third of all
antithrombin orders. For V Leiden/APC resistance, the
functional assay was only ordered about one tenth as
often as the DNA assay. The ratios were not substantially
altered by filtering out orders from anomalous client-
months. The ratios based on the 33 surveyed clients were
similar to those based on the full data set, and were only
modestly affected by filtering out data for clients perform-
ing testing in-house.
Positivity rates are shown in Table 4, along with mean age
and sex distribution corresponding to each test. Of speci-
mens on which tests for both protein C and protein S tests
were ordered, 6.5% were positive (i.e. result below the ref-
erence interval on at least one assay) for both protein C
and protein S deficiency. For specimens on which protein
C, protein S and antithrombin tests were all ordered,
15.7% of these specimens had positive results for two of
the three analytes; 1.2% had positive results for all three.
From 21–54% of results indicating protein S or protein C
deficiency were associated with an INR greater than 1.3
(Table 4).
Discussion
The ordering patterns for thrombophilia tests observed at
our laboratory during the study period do not appear to
be consistent with practices recommended by the CAP
consensus conference. According to these recommenda-
tions, total antigen tests have a much more limited role
than the other assays for protein S, protein C and anti-
thrombin. The fact that they are ordered within an order
of magnitude as often as first-line tests is evidence that cli-
nicians are not aware of the appropriate role of these tests
or of the CAP consensus conference recommendations.
Likewise, the fact that the DNA test for FVL is ordered
almost ten times as often as the functional APC resistance
assay (which has a lower cost and faster turnaround time)
suggests that clinicians are either unaware of the func-
tional assay or else unaware that it is considered an
equally appropriate first-line test in most cases.
Positivity rates for the antithrombin, protein C and pro-
tein S assays were much higher than would be expected
relative to the observed prevalence of FVL and pro-
thrombin G20210A mutations, as well as previously pub-
lished data on the relative frequencies of inherited
thrombophilia defects. Because the V Leiden and pro-
thrombin G20210A mutations are both DNA-based tests,
results of these tests directly measure the heritable defect
frequencies in the population being tested. Assuming that
the patient population for all these assays is reasonably
homogeneous, the expected frequencies for inherited
deficiencies of protein C, protein S and antithrombin
would be roughly an order of magnitude lower. The high
positivity rates for these latter assays, combined with the
high rates of concomitant positivity for multiple analytes
as well as the high frequency of elevated INR on these
specimens (Table 4), suggest that many of these positive
results are actually false positives due to suboptimally
timed testing.
Prior studies have shown variability in the use of these
tests. Bushnell et al. identified non-evidence-based order-
ing by neurologists on patients with ischemic stroke,
based on both observation[15] and survey[16]. Roberto-
rye calculated test order ratios at ARUP Laboratories in
1998 and 1999 for protein C, protein S, antithrombin and
FVL, with similar results to those reported in this
paper[17]. In this previous study, which was based on raw
Table 2: Results of client survey regarding in-house testing for 
thrombophilia tests of interest to this study.
Test Percent of survey respondents performing 
tests in-house (%)
Protein C Functional 12.5
Protein C Total Ag 0.0
Protein S Functional 9.4
Protein S Free Ag 3.1
Protein S Total Ag 0.0
Antithrombin Functional 25.0
Antithrombin Total Ag 3.1
APC Resistance 12.5
Factor V Leiden by PCR 21.8
Table 3: Ratios of test order volumes by defect category (See Methods for explanation)
Raw data (all clients) Filtered data All surveyed clients Surveyed clients not testing in-house
Protein C Functional/Total Ag ratio 1.10 1.09 1.12 1.65
Protein S (Functional+Free Ag)/Total Ag ratio 1.28 1.27 1.21 2.10
Antithrombin Functional/Total Ag ratio 2.10 2.10 2.91 3.50
APC resistance/V Leiden DNA ratio 0.13 0.12 0.15 0.15BMC Clinical Pathology 2008, 8:3 http://www.biomedcentral.com/1472-6890/8/3
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order volumes only, the functional assay to antigen assay
ratios were 0.53, 0.54 and 2.59 for protein C, protein S
and antithrombin, respectively. The analogous ratio for
FVL was 3.71. Because of fluctuations in ARUP's client mix
it is difficult to draw conclusions from the changes in
these numbers over time; nonetheless, both sets of results
demonstrate a considerable degree of questionable order-
ing.
The appropriate role of thrombophilia testing as a whole
has also been discussed in the literature. The CAP confer-
ence recommended that based on available evidence,
anticoagulant therapy for thrombosis should be based
primarily on clinical factors rather than laboratory identi-
fication of one of the above defects. Others have issued
similar recommendations[18]. Proposed indications for
testing include family counseling (in the case of heritable
defects) and clarification of etiology. Most authors advo-
cate selective testing in young patients, those with a rele-
vant family history and/or those with unusual or severe
presentations, though specific recommendations differ by
author[19-23]. It may be the case, in fact, that the most
widespread problem in thrombophilia testing is not test
selection per se, but rather ordering any of these tests in
the first place on patients who have clear nonhereditary
precipitants of thrombosis[2]. Given our data set, we
could not determine the proportion of patients with
thrombosis who were worked up for hereditary throm-
bophilia, nor could we determine the extent to which test
results were used to drive therapy.
The financial implications of inappropriate throm-
bophilia testing are considerable. At ARUP we have
observed that thrombophilia tests account for a dispro-
portionately high fraction of our clients' sendout test
budgets. Ordering antigenic and functional tests for pro-
tein C, protein S and antithrombin, along with a DNA test
for the V Leiden mutation on a hypothetical Medicare
patient in Utah would cost Medicare $141.85 in reim-
bursement based on 2005 rates[24]. Billed charges would
be considerably higher. At least as important as direct test
costs are the downstream costs associated with follow up
care. A false-positive protein S result, for example, might
lead to repeat diagnostic testing, additional office visits
and/or anticoagulant therapy. The sum of these costs
could dwarf the cost of the initial protein S assay.
The implications for patient safety are arguably more
important than the financial implications. To the extent
that either anticoagulant therapy or genetic counseling
were to rely on incomplete or faulty laboratory diagnosis,
a patient may be put at risk.
The fact that some of ARUP's clients perform the func-
tional tests in-house indicates a likely bias in our full data
set. We believe this bias to be modest, however. First, bas-
ing the volume ratios only on clients known to not per-
form any of the relevant tests in-house did not markedly
alter our findings (Table 3). Second, although CAP Survey
participation data indicates that laboratories more often
perform functional than total antigen testing for these
analytes, it also indicates that only a minority of coagula-
tion laboratories perform any of the tests in this study at
all.
Another limitation of this study design was the lack of
linked clinical data. In this absence we could not separate
clinicians' ordering decisions from the interpretation of
these orders at the local laboratory. For example, if a clini-
cian were to write "Protein C" on a requisition form, and
if this were interpreted by local laboratory personnel as an
order for the total antigen test, then the latter order would
be the only one identified in this study. Also, we assumed
that these tests were ordered for venous thromboses, but
it is possible that many of these tests could have been
ordered for arterial thromboses and/or other diag-
noses[16]. Finally, we could not directly assess which
patient may have had an acute thrombosis or been on
Table 4: Positivity rates and patient characteristics by test ordered.*
Positivity Fraction of positives which also had INR>1.3 Median Age % Female
Protein S Functional 17.7% 21.2% 46 65.7%
Protein S Total Ag 4.8% 40.5% 47 63.0%
Protein S Free Ag 18.5% 25.0% 39 67.4%
Protein C Functional 13.7% 53.8% 46 65.4%
Protein C Total Ag 12.9% 33.3% 47 62.9%
Antithrombin Functional 7.5% N/A 46 65.8%
Antithrombin Antigen 14.3% N/A 46 65.3%
APC resistance 17.7% N/A 46 65.7%
V Leiden mutation 12.3% N/A 47 64.1%
Prothrombin G20210A mutation 4.9% N/A 46 64.1%
*Positivity for V Leiden and prothrombin mutations includes both heterozygotes and homozygotes; for the remaining assays it includes all results 
falling below the lower limit of the reported reference interval.BMC Clinical Pathology 2008, 8:3 http://www.biomedcentral.com/1472-6890/8/3
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anticoagulant therapy at the time of testing; we could only
infer this indirectly through prothrombin time results and
relative positivity rates.
Out of 179 recommendations from the CAP consensus
conference[3], our study only considered those which
concerned test ordering and for which compliance could
be assessed through analysis of laboratory data alone, i.e.
in the absence of clinical correlation. The findings
reported here therefore do not apply to the entire set of
conference recommendations. For example, many of the
recommendations related to testing methodology were
directed toward laboratory professionals, and these may
have been more widely adopted. It seems reasonable to
assert, however, that our findings reflect a general lack of
adoption of conference recommendations by ordering cli-
nicians, possibly due to a lack of awareness.
Recommendations such as those generated by this CAP
consensus conference fill a critical role in aggregating and
synthesizing medical knowledge[25]. It is true that the lit-
erature on adoption of clinical practice guidelines into
routine practice shows a mixed record[18]; nonetheless, a
reasonable step toward broader dissemination of these
thrombophilia test ordering recommendations might be
consolidation into a single concise guideline for inclusion
in resources such as the National Guideline Clearing-
house[5]. As a complementary approach, laboratories
might consider incorporating some of this guidance into
interpretive statements attached as footnotes to individual
laboratory results. Such statements might include clarify-
ing that the reference intervals are valid only for individ-
ual free of thrombosis and not on anticoagulant therapy.
Conclusion
Our findings suggest that a substantial proportion of
thrombophilia ordering is not consistent with the recom-
mendations of the CAP consensus conference. Some
patients may receive suboptimal care as a result. Laborato-
ries and health care provider organizations need better
mechanisms to promote appropriate utilization of throm-
bophilia tests.
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